Intensity Therapeutics Restarts Trials, but Capital Remains the Critical Constraint

Micro-cap biotech restarts two clinical studies with amended protocols and upbeat early data, but the path to completion hinges on continued ATM raises.

INTS · Earnings Call · 2026-08-11

A Deliberate, Capital-Constrained Resumption

Intensity Therapeutics (INTS) reported its Q2 2026 results on August 11, and the narrative is one of careful progress against a backdrop of limited funds. The company ended the quarter with $9.5 million in cash, but has since raised an additional $1.3 million via its ATM facility, and management guided to a burn rate of about $1 million per month for the back half of 2026. As CFO Joe Talamo put it, the plan is to continue tapping the ATM to keep the INVINCIBLE-3 study moving forward:

So you can see with today's guidance we're estimating a monthly cash burn of $1 million per month for the balance of 2026. That, given where we are today, what we need, the INVINCIBLE-3 study, it's about an incremental $30 million to complete that study.
Joseph Talamo, Chief Financial Officer · 2026-08-11

That $30 million is a tall order for a company with a market cap of just over $12 million, and the ATM is currently the only reliable source of incremental capital. Management acknowledged that "it's not enough to open up all the sites immediately" and that "we would need to bring in certainly much more capital before the end of the year before we would open up all the sites by the end of the year." The company's cash runway is reflected in the fundamentals: Cash runway stood at 5.6 quarters as of the latest filing, a dramatic improvement from the 0.9x of Q1 2025, yet it remains insufficient to bankroll a full, multicenter oncology study.

INVINCIBLE-3: Restarting with a Tightened Protocol

The INVINCIBLE-3 trial, a randomized Phase III in soft tissue sarcomas, was paused in March 2025 due to funding. Enrollment resumed in a limited number of U.S. sites in April 2026, but the company has used the pause to amend the protocol with input from investigators. Key changes include excluding tumors above 15 cm (some patients had 39 cm tumors) and implementing a central radiology read. As CEO Lewis Bender explained: “People were coming in with, believe it or not, 39-centimeter-sized tumors. And that's just not treatable from any perspective. And so that was one of the exclusion criteria.” — Lewis Bender, President and CEO · 2026-08-11 The amended protocol has been cleared by the FDA, and the company is preparing documentation to open sites in five European countries. However, the full restart is contingent on capital. The 21 patients enrolled before the pause continue to be followed, though their inclusion in the primary analysis is still under statistical review—a point Bender acknowledged: "We haven't really looked at those patients in any detail for obvious reasons, but we will make a decision on whether to include them at the appropriate time." The standard of care in second- and third-line sarcoma remains inadequate, with 3-year survival under 10%, which underpins the urgency.

INVINCIBLE-4: Promising Early Data, but a Regimen Change

The INVINCIBLE-4 study, a Phase II in early-stage triple-negative breast cancer (TNBC), had also been paused due to localized skin toxicity. The amended protocol now uses a single injection with a reduced volume. Enrollment has resumed in Switzerland and a site has opened in France. The preliminary data from 14 patients (7 per arm) were encouraging: 71% of Cohort A (INT230-6 plus standard of care) achieved a pathologic complete response (pCR) versus 42% in Cohort B. Bender noted that these were larger tumors than the KEYNOTE-522 trial, which makes the difference more striking: “So they're randomized, they're balanced. They're all triple-negative patients. The tumors ranged in size quite broadly as you saw, the mean was 3.1, I think the median was 2.4... So they're treating the harder-to-treat population.” — Lewis Bender, President and CEO · 2026-08-11 However, the company has not yet seen data from patients treated under the amended regimen. The plan is to add seven new patients to Cohort A to replace the original seven, essentially restarting the efficacy comparison. Bender emphasized that the complete response signal is the key metric, but also highlighted a trend toward fewer Grade 3 adverse events, which could differentiate INT230-6 from the harsh immunochemotherapy backbone.

Data, Publications, and Partnerships

Intensity also touted a peer-reviewed publication in eBioMedicine (Lancet group) from its Phase I/II IT-01 study, reporting a disease control rate of 75%, median overall survival of 11.7 months, and an abscopal effect in nearly 20% of patients who received over 40% of their tumor burden. This publication is a credibility boost and has already attracted interest from potential partners. At BIO in late June, the company held over 20 meetings, many requested by the other side. Bender described the interest as "very early" but expressed openness to various deal structures: "There are multinational companies that will probably want global rights that we're talking to. There are regional players that want anything from 1 country to several countries in their region." “We're very fortunate that many companies requested to meet with us. We had great meetings. We're open to a lot of ideas.” — Lewis Bender, President and CEO · 2026-08-11 These business development activities are far from monetized, but they provide a potential non-dilutive path beyond the ATM. As Bender said, "if a big bolus comes in, then obviously we can turbocharge the study."

Assessment

Intensity Therapeutics is a micro-cap with a genuine shot at addressing an unmet need, but its fate is heavily dependent on its ability to raise capital and execute on a tight timeline. The clinical data, while early, are encouraging—especially the pCR improvement in TNBC and the abscopal effect in later-stage patients. The restart is real, but the company is only slowly increasing enrollment. The new patients in both studies will be key to validating the amended protocols. Investors who follow the space will need to watch cash burn, ATM activity, and any partnership announcements. If capital remains constrained, the studies could again stall; if a partnership materializes, the story could accelerate quickly. In the near term, the stock has risen 17% since the report, but the market is still pricing in substantial risk. The current financial position—with a net loss of ~$2-3M per quarter and no revenues—means the company burns roughly $1M per month. The runway, while improved, is still measured in quarters, not years. The next few months will be pivotal as we see whether the restarted studies enroll as anticipated and whether any of the BIO conversations translate into concrete partnership deals.